Boothbay Fund Management’s Arbutus Biopharma ABUS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $810K | Buy |
262,277
+100,000
| +62% | +$309K | 0.02% | 591 |
|
|
2025
Q1 | $566K | Hold |
162,277
| – | – | 0.01% | 668 |
|
|
2024
Q4 | $531K | Sell |
162,277
-450,000
| -73% | -$1.47M | 0.01% | 716 |
|
|
2024
Q3 | $2.36M | Hold |
612,277
| – | – | 0.05% | 382 |
|
|
2024
Q2 | $1.89M | Hold |
612,277
| – | – | 0.04% | 436 |
|
|
2024
Q1 | $1.58M | Buy |
612,277
+158,649
| +35% | +$409K | 0.03% | 493 |
|
|
2023
Q4 | $1.13M | Sell |
453,628
-38,093
| -8% | -$95.2K | 0.03% | 579 |
|
|
2023
Q3 | $998K | Hold |
491,721
| – | – | 0.02% | 634 |
|
|
2023
Q2 | $1.13M | Sell |
491,721
-132,266
| -21% | -$304K | 0.02% | 640 |
|
|
2023
Q1 | $1.89M | Sell |
623,987
-88,680
| -12% | -$269K | 0.04% | 576 |
|
|
2022
Q4 | $1.66M | Sell |
712,667
-54,733
| -7% | -$128K | 0.04% | 550 |
|
|
2022
Q3 | $1.47M | Buy |
767,400
+215,132
| +39% | +$411K | 0.04% | 617 |
|
|
2022
Q2 | $1.5M | Buy |
552,268
+61,645
| +13% | +$167K | 0.04% | 591 |
|
|
2022
Q1 | $1.46M | Buy |
490,623
+31,981
| +7% | +$95.3K | 0.03% | 598 |
|
|
2021
Q4 | $1.78M | Buy |
458,642
+298,642
| +187% | +$1.16M | 0.04% | 431 |
|
|
2021
Q3 | $686K | Buy |
160,000
+100,000
| +167% | +$429K | 0.02% | 768 |
|
|
2021
Q2 | $182K | Buy |
60,000
+16,782
| +39% | +$50.9K | 0.01% | 1384 |
|
|
2021
Q1 | $144K | Sell |
43,218
-4,062
| -9% | -$13.5K | 0.01% | 1195 |
|
|
2020
Q4 | $168K | Buy |
47,280
+34,062
| +258% | +$121K | 0.01% | 961 |
|
|
2020
Q3 | $41K | Buy |
+13,218
| New | +$41K | ﹤0.01% | 875 |
|
|
2020
Q1 | – | Sell |
-21,261
| Closed | -$59K | – | 724 |
|
|
2019
Q4 | $59K | Buy |
+21,261
| New | +$59K | 0.01% | 690 |
|
|
2018
Q3 | – | Sell |
-48,000
| Closed | -$350K | – | 641 |
|
|
2018
Q2 | $350K | Buy |
+48,000
| New | +$350K | 0.03% | 324 |
|